Russia’s Sputnik V Vaccine Rollout Begins In India

120
MOSCOW, RUSSIA - AUGUST 6, 2020: Ampoules contain a vaccine for COVID-19 developed by Gamaleya Research Institute of Epidemiology and Microbiology under the Russian Healthcare Ministry. A two-component adenoviral vector-based vaccine, Gam-COVID-Vak will be available to public on January 1, 2021. Russian Direct Investment Fund and Gamaleya Research Center/TASS THIS IMAGE WAS PROVIDED BY A THIRD PARTY. EDITORIAL USE ONLY Ðîññèÿ. Ìîñêâà. Âàêöèíà äëÿ ïðîôèëàêòèêè íîâîé êîðîíàâèðóñíîé èíôåêöèè COVID-19, ðàçðàáîòàííàÿ Íàöèîíàëüíûì èññëåäîâàòåëüñêèì öåíòðîì ýïèäåìèîëîãèè è ìèêðîáèîëîãèè èìåíè àêàäåìèêà Í.Ô. Ãàìàëåè Ìèíçäðàâà Ðîññèè. Ãàì-ÊÎÂÈÄ-Âàê - âåêòîðíàÿ äâóõêîìïîíåíòíàÿ âàêöèíà íà îñíîâå àäåíîâèðóñà ÷åëîâåêà.  ãðàæäàíñêèé îáîðîò ïðåïàðàò ïîñòóïèò 1 ÿíâàðÿ 2021 ãîäà. ÐÔÏÈ è Öåíòð èìåíè Ãàìàëåè/ÒÀÑÑ ÔÎÒÎ ÏÐÅÄÎÑÒÀÂËÅÍÎ ÒÐÅÒÜÅÉ ÑÒÎÐÎÍÎÉ. ÒÎËÜÊÎ ÄËß ÐÅÄÀÊÖÈÎÍÍÎÃÎ ÈÑÏÎËÜÇÎÂÀÍÈß

Russia’s Sputnik V Vaccine Rollout Begins In India

By AFP

India on Friday started inoculating its population with Russia’s Sputnik V coronavirus vaccine, the jab’s developers said.

The Russian Direct Investment Fund (RDIF), which helped finance the jab, said vaccination started in the southern city of Hyderabad on Friday, making Sputnik V the “first foreign-made vaccine that is used in India”.

It said a first batch of the two-dose vaccine arrived in India on May 1 and a second delivery is expected in the next few days.

“RDIF stands ready to support our partners in India to launch a full-scale vaccination with Sputnik V as soon as possible,” the fund’s CEO Kirill Dmitriev said in a statement.

Sputnik was approved in India in mid-April under emergency use authorisation.

A number of leading India-based drugmakers, including Virchow Biotech and Hetero Biopharma, have agreements for local production of Sputnik V with the aim to produce over 850 million doses of the jab a year.

According to the RDIF, Russia’s vaccine, which is named after the Soviet-era satellite, has been registered in 65 countries.

It has not yet been approved by the European Medicines Agency (EMA) or the United States’ Food and Drug Administration (FDA).

Some Western countries have been wary of Sputnik V over concerns the Kremlin would use it as a soft-power tool to advance its interests.

Moscow registered the jab in August before large-scale clinical trials, but leading medical journal The Lancet has since said it is safe and more than 90 percent effective.